Myc induced miR-144/451 contributes to the acquired imatinib resistance in chronic myelogenous leukemia cell K562

Biochemical and Biophysical Research Communications

Volumn 425, Issue 2, 2012, Pages 368-373

  Liu, Li ^a   Wang, Sitao ^a   Chen, Renan ^a   Wu, Yanlan ^a   Zhang, Bei ^a   Huang, Siyong ^a   Zhang, Jingyi ^a   Xiao, Fang ^a   Wang, Meng ^a   Liang, Yingmin ^a  

^a FOURTH MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

C myc; Chronic myelogenous leukemia; Imatinib resistance; MiR 144 451

Indexed keywords

BETA ACTIN; IMATINIB; MICRORNA; MICRORNA 144; MICRORNA 451; MYC PROTEIN; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CANCER RESISTANCE; CELL STRAIN K 562; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; DRUG SENSITIZATION; GENE EXPRESSION REGULATION; GENE TARGETING; ONCOGENE C MYC; PRIORITY JOURNAL; UPREGULATION;

ANTINEOPLASTIC AGENTS; DRUG RESISTANCE, NEOPLASM; GENE KNOCKDOWN TECHNIQUES; HUMANS; K562 CELLS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MICRORNAS; PIPERAZINES; PROTO-ONCOGENE PROTEINS C-MYC; PYRIMIDINES;

EID: 84865386963     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2012.07.098     Document Type: Article

References (32)

1. Melo J.V. The diversity of BCR-ABL fusion proteins and their relationship to leukemia phenotype. Blood 1996, 88:2375-2384.
2. Ren R. Mechanisms of BCR-ABL in the pathogenesis of chronic myelogenous leukaemia. Nat. Rev. Cancer 2005, 5:172-183.
3. Cohen M.H., Johnson J.R., Pazdur R. U.S. Food and Drug Administration Drug Approval Summary: conversion of imatinib mesylate (STI571; Gleevec) tablets from accelerated approval to full approval. Clin. Cancer Res. 2005, 11:12-19.
4. le Coutre P., Tassi E., Varella-Garcia M., Barni R., Mologni L., Cabrita G., Marchesi E., Supino R., Gambacorti-Passerini C. Induction of resistance to the Abelson inhibitor STI571 in human leukemic cells through gene amplification. Blood 2000, 95:1758-1766.
5. Gorre M.E., Mohammed M., Ellwood K., Hsu N., Paquette R., Rao P.N., Sawyers C.L. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 2001, 293:876-880.
6. Dai Y., Rahmani M., Corey S.J., Dent P., Grant S. A Bcr/Abl-independent, Lyn-dependent form of imatinib mesylate (STI-571) resistance is associated with altered expression of Bcl-2. J. Biol. Chem. 2004, 279:34227-34239.
7. Nambu T., Araki N., Nakagawa A., Kuniyasu A., Kawaguchi T., Hamada A., Saito H. Contribution of BCR-ABL-independent activation of ERK1/2 to acquired imatinib resistance in K562 chronic myeloid leukemia cells. Cancer Sci. 2010, 101:137-142.
8. Quentmeier H., Eberth S., Romani J., Zaborski M., Drexler H.G. BCR-ABL1-independent PI3Kinase activation causing imatinib-resistance. J. Hematol. Oncol. 2011, 4:6.
9. Kalle A.M., Sachchidanand S., Pallu R. Bcr-Abl-independent mechanism of resistance to imatinib in K562 cells: Induction of cyclooxygenase-2 (COX-2) by histone deacetylases (HDACs). Leuk. Res. 2010, 34:1132-1138.
10. Arunasree K.M., Roy K.R., Anilkumar K., Aparna A., Reddy G.V., Reddanna P. Imatinib-resistant K562 cells are more sensitive to celecoxib, a selective COX-2 inhibitor: role of COX-2 and MDR-1. Leuk. Res. 2008, 32:855-864.
11. Xie S., Lin H., Sun T., Arlinghaus R.B. Jak2 is involved in c-Myc induction by Bcr-Abl. Oncogene 2002, 21:7137-7146.
12. Ambros V. The functions of animal microRNAs. Nature 2004, 431:350-355.
13. Calin G.A., Croce C.M. MicroRNA signatures in human cancers. Nat. Rev. Cancer 2006, 6:857-866.
14. Osada H., Takahashi T. MicroRNAs in biological processes and carcinogenesis. Carcinogenesis 2007, 28:2-12.
15. Zhang B., Pan X., Cobb G.P., Anderson T.A. MicroRNAs as oncogenes and tumor suppressors. Dev. Biol. 2007, 302:1-12.
16. Lu J., Getz G., Miska E.A., Alvarez-Saavedra E., Lamb J., Peck D., Sweet-Cordero A., Ebert B.L., Mak R.H., Ferrando A.A., Downing J.R., Jacks T., Horvitz H.R., Golub T.R. MicroRNA expression profiles classify human cancers. Nature 2005, 435:834-838.
17. Wang X.S., Zhang J.W. The microRNAs involved in human myeloid differentiation and myelogenous/myeloblastic leukemia. J. Cell. Mol. Med. 2008, 12:1445-1455.
18. Machova Polakova K., Lopotova T., Klamova H., Burda P., Trneny M., Stopka T., Moravcova J. Expression patterns of microRNAs associated with CML phases and their disease related targets. Mol. Cancer 2011, 10:41.
19. Lopotova T., Zackova M., Klamova H., Moravcova J. MicroRNA-451 in chronic myeloid leukemia: miR-451-BCR-ABL regulatory loop?. Leuk. Res. 2011, 35:974-977.
20. Bandres E., Bitarte N., Arias F., Agorreta J., Fortes P., Agirre X., Zarate R., Diaz-Gonzalez J.A., Ramirez N., Sola J.J., Jimenez P., Rodriguez J., Garcia-Foncillas J. MicroRNA-451 regulates macrophage migration inhibitory factor production and proliferation of gastrointestinal cancer cells. Clin. Cancer Res. 2009, 15:2281-2290.
21. Bitarte N., Bandres E., Boni V., Zarate R., Rodriguez J., Gonzalez-Huarriz M., Lopez I., Sola J.J., Alonso M.M., Fortes P., Garcia-Foncillas J. Microrna-451 is Involved in the Self-Renewal, Tumorigenicity and Chemoresistance of Colorectal Cancer Stem Cells. Stem Cells 2011.
22. Scherr M., Battmer K., Winkler T., Heidenreich O., Ganser A., Eder M. Specific inhibition of bcr-abl gene expression by small interfering RNA. Blood 2003, 101:1566-1569.
23. Chang T.C., Yu D., Lee Y.S., Wentzel E.A., Arking D.E., West K.M., Dang C.V., Thomas-Tikhonenko A., Mendell J.T. Widespread microRNA repression by Myc contributes to tumorigenesis. Nat. Genet. 2008, 40:43-50.
24. Pyndiah S., Tanida S., Ahmed K.M., Cassimere E.K., Choe C., Sakamuro D. c-MYC suppresses BIN1 to release poly(ADP-ribose) polymerase 1: a mechanism by which cancer cells acquire cisplatin resistance. Sci. Signal. 2011, 4:ra19.
25. Porro A., Iraci N., Soverini S., Diolaiti D., Gherardi S., Terragna C., Durante S., Valli E., Kalebic T., Bernardoni R., Perrod C., Haber M., Norris M.D., Baccarani M., Martinelli G., Perini G. C-MYC oncoprotein dictates transcriptional profiles of ATP-binding cassette transporter genes in chronic myelogenous leukemia CD34+ hematopoietic progenitor cells. Mol. Cancer Res. 2011, 9:1054-1066.
26. Liu L., Chen R., Huang S., Wu Y., Li G., Liu Q., Yin D., Liang Y. Knockdown of SOD1 sensitizes the CD34+ CML cells to imatinib therapy. Med. Oncol. 2011, 28:835-839.
27. Pehlivan M., Sercan Z., Sercan H.O. SFRP1 promoter methylation is associated with persistent Philadelphia chromosome in chronic myeloid leukemia. Leuk. Res. 2009, 33:1062-1067.
28. Hu Y., Chen Y., Douglas L., Li S. Beta-Catenin is essential for survival of leukemic stem cells insensitive to kinase inhibition in mice with BCR-ABL-induced chronic myeloid leukemia. Leukemia 2009, 23:109-116.
29. Alex R., Sozeri O., Meyer S., Dildrop R. Determination of the DNA sequence recognized by the bHLH-zip domain of the N-Myc protein. Nucleic Acids Res. 1992, 20:2257-2263.
30. Herold S., Wanzel M., Beuger V., Frohme C., Beul D., Hillukkala T., Syvaoja J., Saluz H.P., Haenel F., Eilers M. Negative regulation of the mammalian UV response by Myc through association with Miz-1. Mol. Cell 2002, 10:509-521.
31. Seoane J., Le H.V., Massague J. Myc suppression of the p21(Cip1) Cdk inhibitor influences the outcome of the p53 response to DNA damage. Nature 2002, 419:729-734.
32. Staller P., Peukert K., Kiermaier A., Seoane J., Lukas J., Karsunky H., Moroy T., Bartek J., Massague J., Hanel F., Eilers M. Repression of p15INK4b expression by Myc through association with Miz-1. Nat. Cell Biol. 2001, 3:392-399.